DVA Quote, Financials, Valuation and Earnings

Quest Diagnostics has a net margin of 7.87% compared to DaVita's net margin of 8.47%. DaVita's return on equity of 38.64% beat Quest Diagnostics's return on equity of 12.99%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 6.66%. On the other hand Quest Diagnostics has an analysts' consensus of $177.10 which suggests that it could grow by 5.44%. Given that DaVita has higher upside potential than Quest Diagnostics, analysts believe DaVita is more attractive than Quest Diagnostics.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.91%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.79% to investors and pays a quarterly dividend of $0.75 per share. DaVita pays -- of its earnings as a dividend. Quest Diagnostics pays out 38% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Quest Diagnostics quarterly revenues of $2.6B. DaVita's net income of $259.3M is higher than Quest Diagnostics's net income of $222M. Notably, DaVita's price-to-earnings ratio is 14.37x while Quest Diagnostics's PE ratio is 21.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.05x versus 1.93x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Encompass Health has a net margin of 7.87% compared to DaVita's net margin of 8.61%. DaVita's return on equity of 38.64% beat Encompass Health's return on equity of 17.79%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 6.66%. On the other hand Encompass Health has an analysts' consensus of $117.25 which suggests that it could grow by 14.86%. Given that Encompass Health has higher upside potential than DaVita, analysts believe Encompass Health is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.77%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.65% to investors and pays a quarterly dividend of $0.17 per share. DaVita pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Encompass Health quarterly revenues of $1.4B. DaVita's net income of $259.3M is higher than Encompass Health's net income of $120.9M. Notably, DaVita's price-to-earnings ratio is 14.37x while Encompass Health's PE ratio is 22.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.05x versus 1.94x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 7.87% compared to DaVita's net margin of 26.88%. DaVita's return on equity of 38.64% beat ResMed's return on equity of 25.56%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 6.66%. On the other hand ResMed has an analysts' consensus of $270.09 which suggests that it could grow by 21.12%. Given that ResMed has higher upside potential than DaVita, analysts believe ResMed is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.93% to investors and pays a quarterly dividend of $0.53 per share. DaVita pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than ResMed quarterly revenues of $1.3B. DaVita's net income of $259.3M is lower than ResMed's net income of $344.6M. Notably, DaVita's price-to-earnings ratio is 14.37x while ResMed's PE ratio is 26.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.05x versus 6.68x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of 7.87% compared to DaVita's net margin of 4.12%. DaVita's return on equity of 38.64% beat US Physical Therapy's return on equity of 3.86%.

DaVita has a consensus price target of $164.57, signalling upside risk potential of 6.66%. On the other hand US Physical Therapy has an analysts' consensus of $108.33 which suggests that it could grow by 49.36%. Given that US Physical Therapy has higher upside potential than DaVita, analysts believe US Physical Therapy is more attractive than DaVita.

DaVita has a beta of 1.044, which suggesting that the stock is 4.414% more volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.634%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.44% to investors and pays a quarterly dividend of $0.45 per share. DaVita pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

DaVita quarterly revenues are $3.3B, which are larger than US Physical Therapy quarterly revenues of $180.4M. DaVita's net income of $259.3M is higher than US Physical Therapy's net income of $7.4M. Notably, DaVita's price-to-earnings ratio is 14.37x while US Physical Therapy's PE ratio is 39.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.05x versus 1.63x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.